BrightSpring Health Services, Inc. (BTSG) Stock: Price, Forecast & Analyst Target
BrightSpring Health Services, Inc. (BTSG) — MoonshotScore 87/100 (Exceptional band), calculated Nov 18, 2026. Price $64.02 (-6.32%), as of the Nov 19, 2026 trading session; market cap $12.7B.
Educational signal · not a buy or sell recommendation · How to read this
BrightSpring Health Services, Inc. · BTSG · NASDAQ · Healthcare · Medical Healthcare Information Services
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): BrightSpring delivers pharmacy and clinical services in patients’ homes and local communities, largely for people covered by government programs or commercial insurance. The case rests on whether rising care volume can keep lifting profit and cash generation while the company carries substantially more debt than cash.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · BrightSpring Health Services (BTSG)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and elite growth, but a strained balance sheet; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 7 of the last 8 reports
- Altman Z 4.99 · Piotroski F 7
- ROE 15.5% · ROA 5.4% · current ratio 1.62
Holding back: balance-sheet strain
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 86 | Exceptional | |
| 87 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 87 | Exceptional | |
| 87 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $64.02 | |
| Change on the day | -6.32% | |
| 52-week range | $30.64–$73.75 | |
| Market capitalisation | $12.7B | — |
| Price / earnings (trailing) | 42.58 | |
| Shares traded on the day | 3.11M | |
| Beta (volatility vs the S&P 500) | 1.78 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for BrightSpring Health Services (BTSG): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 16, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is BrightSpring Health Services (BTSG), and what does it report?
Short answer · as of
BrightSpring is not primarily a healthcare information vendor.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Its revenue comes from pharmacy services, medical care and supportive assistance delivered through clinicians and licensed pharmacists near where patients live, with reimbursement tied to Medicare, Medicaid and private insurance.
Reported revenue therefore reflects a broad mix of medication fulfillment and patient care rather than software subscriptions. The company reports a large revenue base with comparatively narrow gross, operating and net margins, making service mix, reimbursement and operating discipline important to earnings.
What do the latest results show for BrightSpring Health Services (BTSG)?
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
The latest results extended a sustained rise in revenue, gross profit, operating profit and net income. Profit advanced faster than revenue across the recent sequence, while reported revenue and earnings also exceeded market estimates in the latest release.
Cash performance was less linear. Operating cash flow remained positive but fell sharply from the preceding period even as accounting profit increased, so the improvement in earnings has not yet translated into equally steady cash generation. Management expects stronger full-period cash conversion and lower leverage, but that remains an outlook to be tested against reported cash flow.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $4.21B | $100M | $0.45 (diluted) |
| Q2 FY2026 | $3.87B | $87M | $0.39 (diluted) |
| Q1 FY2026 | $3.61B | $74M | $0.34 (diluted) |
| Q4 FY2025 | $3.55B | $77M | $0.35 (diluted) |
What are the financial strengths and risks for BrightSpring Health Services (BTSG)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
BrightSpring has produced positive operating cash flow throughout the reported sequence, and capital spending has remained modest relative to that inflow. The liquidity ratios and quality screens also indicate adequate near-term financial capacity.
Debt is the sharper constraint. Cash and investments cover only a minority of total borrowings, leaving the company in a substantial net-debt position while margins remain thin. A setback in reimbursement, pharmacy economics or care delivery costs could therefore compress earnings quickly and reduce room for acquisitions or balance-sheet flexibility.
What should you watch next at BrightSpring Health Services (BTSG)?
Short answer · as of
Current published price targets run low $70.00 · high $92.00 · consensus $81.36 · median $80.00 against a quoted price of $64.02 (as of Nov 19, 2026).
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Watch whether revenue, gross profit and operating profit continue rising together. Revenue growth without further operating leverage would suggest that added care and pharmacy volume is carrying too much incremental cost.
Cash conversion deserves equal weight: operating cash flow weakened in the latest period, while management has set a materially stronger full-period expectation and is evaluating the capital structure needed to support future growth. The scheduled earnings release should clarify whether cash generation is catching up with profit and whether debt is moving toward management’s stated leverage objective.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does BrightSpring Health Services compare with its peers?
Short answer
BrightSpring Health Services's score ranks 3rd of 6 in the bounded comparison shown, against 5 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
BrightSpring combines pharmacy operations with hands-on clinical and supportive care delivered in homes and communities. That makes it different from a pharmacy distributor, a clinic operator or a healthcare software company viewed in isolation: medication services and patient care sit on the same broad platform.
Its payer exposure also spans government programs and commercial insurance. Compared with businesses concentrated in a single care setting or payer channel, BrightSpring’s breadth can diversify demand, but it also exposes profitability to several reimbursement systems while the consolidated margin remains narrow.
| Company | Price | Market value | Score |
|---|---|---|---|
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $97.31 Nov 18, 2026 | $8.05B | 90 5-pillar Nov 18, 2026 | |
| BrightSpring Health Services (BTSG) — this page | $64.02 | $12.7B | 87 |
| $551.33 Nov 19, 2026 | $7.15B | 85 5-pillar Nov 18, 2026 | |
| $62.10 Nov 19, 2026 | $9.48B | 59 5-pillar Nov 18, 2026 | |
| $40.19 Nov 18, 2026 | $3.90B | 22 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $70.00 – $92.00
- Consensus target
- $81.36
- Median target
- $80.00
Consensus record · Captured .
Measured against a quoted price of $64.02 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 25, 2026
- Transactions
- 25
- Identified insiders
- 7
- Purchases
- 0
- Sales
- 7
- Other transactions
- 18
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held BTSG in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Viking Global | Andreas Halvorsen | Q3 2026 | 0.21% | $69.55M | Trimmed −24.3% shares |
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.07% | $16.42M | New position |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about BrightSpring Health Services (BTSG)?
Common Questions About BTSG (Healthcare)
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does BrightSpring provide in patients’ homes and communities?
BrightSpring provides pharmacy services, clinical care and supportive assistance through licensed pharmacists and clinical professionals. Demand is tied to the medication and care needs of insured patients outside traditional hospital settings.
Why does PharMerica matter to BrightSpring?
PharMerica represents BrightSpring’s pharmacy capability, with dedicated sales, account management and operating leadership. It helps distinguish the company from home-care providers that do not combine patient services with pharmacy operations.
Is BrightSpring’s recent profit improvement producing stronger cash flow?
Accounting profit has risen across the recent reporting sequence, but operating cash flow dropped in the latest period. Management’s cash-conversion outlook makes the gap between earnings and cash a key follow-through test.
How exposed is BrightSpring to Medicare, Medicaid and commercial insurance?
Those payer channels fund the pharmacy and provider services delivered to BrightSpring’s patients. Reported segment figures confirm meaningful Medicaid and commercial-insurance revenue, while the broader business description also identifies Medicare coverage.
What is the BTSG stock price today?
The last price recorded for BrightSpring Health Services, Inc. (BTSG), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the BTSG price target?
The analyst consensus price target for BrightSpring Health Services, Inc. (BTSG), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold BTSG
Funds in our ETF coverage that list BTSG among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| XHS ETF | 2.33% | |
| iShares Russell 2000 ETF (IWM) | 0.30% |